Cyclic GMP EIA Kit, Species Independent

Description

The Cyclic GMP (cGMP) EIA kit is designed to quantitatively measure cGMP present in lysed cells, EDTA plasma, urine, saliva and tissue culture media samples. For samples where the levels of cGMP are expected to be relatively high, the regular format for the assay can be used. For samples with expected low levels of cGMP, an optional acetylation protocol can be used. The kit is unique in that all samples and standards are diluted into an acidic Sample Diluent, which contains special additives and stabilizers, for cGMP measurement. This allows plasma, urine and saliva samples to be read in an identical manner to lysed cells. Acidified samples of cGMP are stable and endogenous phosphodiesterases are inactivated in the Sample Diluent. A cGMP standard is provided to generate a standard curve for the assay and all samples should be read off the standard curve. A clear microtiter plate coated with an antibody to capture mouse IgG is provided and a neutralizing Plate Primer solution is added to all the used wells. Standards or diluted samples, either with or without acetylation, are pipetted into the primed wells. A cGMP-peroxidase conjugate is added to the standards and samples in the wells. The binding reaction is initiated by the addition of a mouse monoclonal antibody to cGMP to each well. After a 2 hour incubation, the plate is washed and substrate is added. The substrate reacts with the bound cGMP-peroxidase conjugate. After a short incubation, the reaction is stopped and the intensity of the generated color is detected in a microtiter plate reader capable of measuring 450 nm wavelength. The concentration of the cGMP in the sample is calculated, after making suitable correction for the dilution of the sample, using software available with most plate readers.

Species Reactivity

Wide Species

Applications

Direct EIA (Enzyme Immunoassay)

Relevant Diseases

Neurological Disorders

Sensitivity

0.28 pmol/ml

Platform

Microplate

Detection Method

Colorimetric Assay

Sample Type

Cell lysates, EDTA Plasma, Saliva, Tissue, Tissue Culture Media, Urine

Assay Type

EIA Kits

Precision

Intra Assay Precision (Regular): Three human urine samples were diluted with Sample Diluent and run in replicates of 20 in an assay. The mean and precision of the calculated cGMP concentrations were: Sample 1- 8.5 pmol/mL, 6.3% CV Sample 2- 4.0 pmol/mL, 7.8% CV Sample 3- 1.2 pmol/mL, 13.6% CV Intra Assay Precision (Acetylated): Three human urine samples were diluted with Sample Diluent, acetylated and run in replicates of 20 in an assay. The mean and precision of the calculated cGMP concentrations were: Sample 1- 8.1 pmol/mL, 3.8% CV Sample 2- 3.8 pmol/mL, 5.2% CV Sample 3- 1.2 pmol/mL, 8.2% CV Inter Assay Precision (Regular): Three human urine samples were diluted with Sample Diluent and run in duplicates in twelve assays run over multiple days by three operators. The mean and precision of the calculated cGMP concentrations were: Sample 1- 8.5 pmol/mL, 6.5% CV Sample 2- 4.3 pmol/mL, 7.0% CV Sample 3- 1.5pmol/mL, 8.3% CV Inter Assay Precision (Acetylated): Three human urine sample weres diluted with Sample Diluent, acetylated and run in duplicates in twelve assays run over multiple days by three operators. The mean and precision of the calculated cGMP concentrations were: Sample 1- 8.7 pmol/mL, 12.3% CV Sample 2- 4.3 pmol/mL, 14.3% CV Sample 3- 1.5 pmol/mL, 14.2% CV

Number Of Samples

39 samples in duplicate

Linear Range

Regular: 0.5 - 32 pmol/ml. Acetylated: 0.3125 - 20 pmol/ml

Components

Coated Clear 96 Well Plates 1 Each
Cyclic GMP Standard 70 µl
StressXpress® Cyclic GMP Antibody 3 ml
StressXpress® Cyclic GMP Conjugate 3 ml
Sample Diluent 28 ml
Plate Primer 5 ml
Acetic Anhydride 2 ml
Triethylamine 4 ml
Wash Buffer Concentrate 30 ml
TMB Substrate 11 ml
Stop Solution 5 ml
Plate Sealer 1 Each

Shipping

Blue Ice

Storage

4°C

Research Use Only

For research use only

Official Name

Cyclic GMP

1. Domek-Lopacinska, K. and Strosznajder, JB. (2005) J Physiol Pharmacol 56 Suppl 2, 15-34.
2. Lucas, K.A. et al. (2000) Pharmacol Rev 52: 375-414.
3. Ashman, DF., et al. (1963), Biochem Biophys Res Comm, 11: 330-4.
4. Potter LR, Abbey-Hosch S, and Dickey DM. (2006) Endocr Rev 27: 47-72.
5. Waldman, SA and Murad, F. (1987) Pharmacol Revs, 39: 163-197.
6. Tremblay J, Gerzer R, and Hamet P. (1988), Adv. 2nd Messanger & Phosphoprotein Res., 22: 319-383.
7. Matsumoto T, Kobayashi T, and Kamata K. (2003) J Smooth Muscle Res 39: 67-86.